Feasibility of magnetic resonance spectroscopy in lung cancer
Research type
Research Study
Full title
Feasibility of magnetic resonance spectroscopy in lung cancer
IRAS ID
168237
Contact name
David B Stobo
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Duration of Study in the UK
0 years, 11 months, 27 days
Research summary
New methods to characterise lung cancer non-invasively (ie performing a scan rather than undertaking surgery or taking a tissue sample with a needle) have scope to improve assessment of patients with this serious illness. Magnetic resonance spectroscopy (MRS) is a type of scan which measures concentrations of chemicals (metabolites) within the body. It is a well-established technique in imaging brain cancers. It has also been more recently studied in assessing prostate, liver and heart. There has been very little exploration of the potential role of MRS in lung cancer.
The proposed feasibility study will recruit 15 patients with proven lung cancer to undergo an MRS scan. The primary question will be whether MRS data can be obtained from lung cancers. The secondary question will be whether there is any indication that the MRS data is reliably obtained by comparing repeated scans showing the concentrations of metabolites from the same region in the tumour. Further scans from different regions in the same tumour and same tumour regions in different patients will be used to look for any patterns in the cancer metabolites which may be indicative of tumour and direct future research.
REC name
West of Scotland REC 5
REC reference
15/WS/0138
Date of REC Opinion
17 Jul 2015
REC opinion
Favourable Opinion